The development of a sustainable and personalised respiratory drug delivery system using the uMIST spray platform

使用 uMIST 喷雾平台开发可持续且个性化的呼吸药物输送系统

• 批准号: 10045506
• 金额: $ 6.34万
• 依托单位: SWEDISH BIOMIMETICS 3000 UMIST TECHNOLOGIES LTD
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10045506
• 关键词: development; sustainable; personalised; respiratory; drug

Optimizing drug delivery is key to improve the treatment of respiratory diseases and overall improve disease management. The metered-dose inhaler (MDI) and the dry powder inhaler (DPI) are mainstay devices in the respiratory drug delivery market. Whilst their portability is attractive, they fall short in drug delivery with studies showing that only 10-20% of the emitted dose is deposited in the lung. The environmental impact of conventional inhalers on climate change must not be overlooked. MDIs, used by 20% of the UK population, use environmentally damaging propellants that contribute to approximately 25% of the General Practice prescribing carbon footprint in the UK. There is an urgent demand for a non-polluting and effective drug delivery device to be developed to improve cost-efficiency, reduce the risk of side effects, and improve patient quality of life.uMIST Technologies Ltd. are focusing on this space and aim to develop a drug delivery device that can make respiratory care in the UK more effective, safe, and eco-friendly. This project focuses on the development of a revolutionary spray technology, named the uMIST spray platform. The environmentally-friendly technology, inspired by nature, mimics the Bombardier Beetles natural defense mechanism, and uses electrical control to employ a unique form of flash boiling, to deliver a highly controllable spray.Initial studies have shown that the platform can deliver significantly higher drug levels to the lung, generating 4x higher fine particle fractions compared to standard inhalers. Further research has demonstrated the ability to adjust droplet size and therefore control the location of drug delivery in the respiratory tract. This presents an opportunity to tailor drug delivery depending on the needs of the patient. This project will enable further development of the platform for use in respiratory drug delivery. Drug stability testing will be conducted to ensure that the spray mechanism does not affect the structural integrity of the active ingredient. The efficacy and compatibility of delivering antibiotics using the spray platform will also be explored. The company will also seek support from regulatory affairs consultants to map out the appropriate route to market.Recent progress has led to commercial engagement with device manufacturing and pharma companies. Whilst promising, general feedback has indicated that companies require more evidence to fully assess the viability of technology and to consider routes for commercialisation. This project would generate significant evidence to support technology development and accelerate further innovation on our path to commercial success.

优化给药方式是提高呼吸系统疾病治疗水平、全面提高疾病管理水平的关键。计量吸入器(MDI)和干粉吸入器(DPI)是呼吸系统药物输送市场的主要设备。虽然它们的便携性很吸引人，但它们在药物输送方面存在不足，研究表明，只有10%-20%的排放剂量储存在肺部。不能忽视常规吸入器对气候变化的环境影响。计量吸入器由20%的英国人口使用，使用的破坏环境的推进剂约占英国规定的碳足迹的25%。人们迫切需要开发一种无污染、有效的药物输送装置，以提高成本效益、减少副作用的风险，并改善患者的生活质量。uMIST Technologies Ltd.正专注于这一领域，目标是开发一种能够使英国的呼吸护理更加有效、安全和环保的药物输送装置。该项目致力于开发一种革命性的喷雾技术，名为UMIST喷雾平台。这项环保技术受到自然的启发，模仿庞巴迪甲虫的自然防御机制，使用电子控制采用独特的闪蒸形式，提供高度可控的喷雾。初步研究表明，该平台可以向肺部释放显著更高的药物水平，产生的细颗粒物分数是标准吸入器的4倍。进一步的研究已经证明了调节液滴大小的能力，从而控制药物在呼吸道中的输送位置。这为根据患者的需要量身定做药物输送提供了机会。该项目将有助于进一步开发用于呼吸道药物输送的平台。将进行药物稳定性测试，以确保喷雾机制不会影响活性成分的结构完整性。还将探索使用喷雾平台输送抗生素的有效性和兼容性。该公司还将寻求监管事务顾问的支持，以制定进入市场的适当路线。最近的进展已导致与设备制造和制药公司的商业接触。虽然前景看好，但普遍的反馈表明，公司需要更多的证据来充分评估技术的可行性，并考虑商业化的途径。这个项目将产生重要的证据来支持技术开发，并加快我们在商业成功道路上的进一步创新。